

# Role of Vitamin D on glycemic control and oxidative stress in type 2 diabetes mellitus

Mostafa Saif-Elnasr, Iman M Ibrahim, Manal M Alkady

Department of Radiation Health Research, National Center for Radiation Research and Technology, Atomic Energy Authority, Nasr City, Cairo, Egypt

**Background:** Vitamin D deficiency may play a key role in the development of impaired glucose tolerance, type 2 diabetes mellitus (T2DM), and metabolic syndrome. Several studies have shown that Vitamin D has an antioxidant property. We aimed to investigate 25-hydroxy Vitamin D (25[OH]D) levels in patients with T2DM and in nondiabetic healthy controls and to ascertain the impact of 25(OH)D levels on glycemic control and oxidative stress in T2DM patients. **Materials and Methods:** Thirty male patients with T2DM and twenty age- and socioeconomic status-matched male healthy controls were included in the study. Fasting and postprandial blood sugar and glycated hemoglobin (HbA1c) were measured. Enzyme activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) was determined by spectrophotometric assay, and serum levels of 25(OH)D were measured using radioimmunoassay. **Results:** Serum Vitamin D levels were significantly lower in patients with T2DM than healthy controls ( $P = 0.015$ ). There was a significantly lower GPx activity in patients with T2DM than controls ( $P = 0.048$ ), but the difference in SOD activity did not reach statistical significance. There was a significant negative correlation between serum Vitamin D levels and HbA1c ( $P = 0.016$ ), but no statistical correlation was shown between serum Vitamin D levels and GPx and SOD. **Conclusion:** We conclude that low level of Vitamin D might play a significant role in T2DM pathogenesis. Hence, Vitamin D supplementation may improve glycemic control and oxidative stress in T2DM.

**Key words:** Glycemic control, oxidative stress, type 2 diabetes mellitus, Vitamin D

**How to cite this article:** Saif-Elnasr M, Ibrahim IM, Alkady MM. Role of Vitamin D on glycemic control and oxidative stress in type 2 diabetes mellitus. J Res Med Sci 2017;22:22.

## INTRODUCTION

Type 2 diabetes mellitus (T2DM), a metabolic disorder, is a major global health-care problem.<sup>[1,2]</sup> The World Health Organization has predicted that the global prevalence of diabetes will increase from 2.8% in 2000 to 4.4% in 2030.<sup>[1]</sup> A main function of Vitamin D is to regulate calcium and phosphorus homeostasis and bone metabolism.<sup>[3]</sup> Vitamin D may influence several nonskeletal medical conditions, including cardiovascular disease, cancer, autoimmune disorders, psoriasis, multiple sclerosis, and T2DM.<sup>[4-6]</sup> It has been reported that there is an inverse relationship between circulating levels of Vitamin D and the prevalence of T2DM. In fact, Vitamin D deficiency has been suggested as a risk factor for T2DM.<sup>[7,8]</sup> Some studies have shown

that Vitamin D may play a functional role on glucose tolerance through its effects on insulin secretion and insulin sensitivity.<sup>[9]</sup> Moreover, Vitamin D seems to affect glucose homeostasis and found to be inversely related to glycated hemoglobin (HbA1c) levels in gestational diabetes mellitus.<sup>[10]</sup>

In diabetes, oxidative stress is caused by both an increased formation of plasma-free radicals and a reduction in antioxidant defenses. Hyperinsulinemia and hyperglycemia may enhance the production of free radicals and induce oxidative stress.<sup>[11]</sup> There is considerable evidence that the oxidative stress plays a key role in insulin resistance, impaired insulin secretion, and many of the complications of diabetes such as micro-/macro-vascular damage.<sup>[12,13]</sup> Superoxide dismutase (SOD) and glutathione peroxidase (GPx)

### Access this article online

Quick Response Code:



Website:  
[www.jmsjournal.net](http://www.jmsjournal.net)

DOI:  
10.4103/1735-1995.200278

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**Address for correspondence:** Dr. Mostafa Saif-Elnasr, Department of Radiation Health Research, National Center for Radiation Research and Technology, Atomic Energy Authority, P.O. Box 29, Nasr City, Cairo, Egypt. E-mail: [mostafa\\_saif\\_elnasr@yahoo.com](mailto:mostafa_saif_elnasr@yahoo.com)

**Received:** 28-08-2016; **Revised:** 15-10-2016; **Accepted:** 30-11-2016

are antioxidant enzymes that protect the body against active oxygen-free radicals.<sup>[14,15]</sup> Some experimental studies showed that Vitamin D may have antioxidant properties by modifying some of the antioxidant enzymes.<sup>[16,17]</sup> Therefore, the aim of this study was to investigate the levels of 25-hydroxy Vitamin D (25[OH]D) in patients with T2DM and in nondiabetic healthy controls and to ascertain the impact of 25(OH)D levels on glycemic control and oxidative stress in T2DM patients.

## MATERIALS AND METHODS

This is a case-control study including thirty cases. Inclusion criteria were all cases diagnosed as male patients with T2DM, aged 36–53 years, attending the outpatient clinics of Kasr El Ainy Hospital, Cairo University. Twenty healthy males of comparable age and socioeconomic status served as a control group. The study was conducted in October 2014. Exclusion criteria included use of drugs which affect calcium and bone metabolism, chronic disorders of liver and kidney, cancer, endocrinology disorders such as hypo- or hyper-thyroidism and hyperparathyroidism, insulin injection, use of anticonvulsion drugs, Vitamin D, and calcium supplementation. A written informed consent of participation in the study was taken from all participants. This study was approved by the Committee of Ethics and Research of the university hospital. Weight and height were measured, and the body mass index (BMI) was calculated by dividing body weight by squared height ( $\text{kg}/\text{m}^2$ ). Venous blood samples were drawn in a fasting state from all the participants. Blood samples were left to clot at room temperature and centrifuged, and the serum was separated and stored at  $-20^\circ\text{C}$  until further analysis.

- Serum glucose concentrations (fasting blood sugar [FBS] and postprandial blood sugar [PP]) were measured by glucose oxidase method (Beckman Glucose Analyzer, Fullerton, CA, USA)
- HbA1c for patients was measured by affinity chromatography test using Biosystem kit, USA
- Serum levels of 25(OH)D were determined using radioimmunoassay (RIA) technique by using 25(OH)D  $^{125}\text{I}$  RIA kit (DiaSorin, USA)
- SOD activity was determined using the method of Sun *et al.*<sup>[18]</sup> GPx activity was measured by the method of Paglia and Valentine.<sup>[19]</sup>


### Statistical analysis

The results were expressed as mean  $\pm$  standard error. The statistical difference between groups was analyzed using Student's *t*-test. Pearson's correlation analysis was performed to determine the relationships between variables. The results were considered significant at  $P < 0.05$ . The statistical calculations were done using Statistical Package for the Social Sciences version 15

software, while the presentations were performed using Microsoft Excel 2007.

## RESULTS

Serum Vitamin D levels were significantly lower in patients with T2DM than healthy controls ( $P = 0.015$ ) [Figure 1]. Patients with T2DM had higher BMI as well as FBS and PP than healthy controls ( $P = 0.012$ ,  $P = 0.000$ , and  $P = 0.000$ , respectively) [Table 1]. There was a significantly lower GPx activity in patients with T2DM as compared with those of healthy controls ( $P = 0.048$ ), but the difference in SOD activity did not reach statistical significance [Table 1]. Table 2 illustrates the correlation between different studied



**Figure 1:** Serum Vitamin D levels (mean  $\pm$  standard error) in healthy controls and patients with diabetes ( $P = 0.015$ )

**Table 1:** Age, body mass index, fasting blood sugar, postprandial blood sugar and antioxidant enzymes activity of the studied groups (mean  $\pm$  standard error)

	Controls (n=20)	Patients (n=30)	P
Age (years)	47.00 $\pm$ 1.770	43.69 $\pm$ 1.425	0.161
BMI ( $\text{kg}/\text{m}^2$ )	27.50 $\pm$ 0.749	30.03 $\pm$ 0.482	0.012
FBS (mg/dl)	84.80 $\pm$ 3.399	151.31 $\pm$ 6.871	0.000
PP (mg/dl)	128.90 $\pm$ 2.350	216.40 $\pm$ 10.087	0.000
GPx (IU/ml)	123.43 $\pm$ 1.08	119.15 $\pm$ 1.75	0.048
SOD (IU/ml)	85.01 $\pm$ 0.92	84.96 $\pm$ 0.98	0.971

When  $P < 0.05$ , it is statistically significant. BMI = Body mass index; FBS = Fasting blood sugar; PP = Postprandial blood sugar; GPx = Glutathione peroxidase; SOD = Superoxide dismutase

**Table 2:** Correlation between different studied parameters in the group of patients

	r	P
Vitamin D and HbA1c	-0.649	0.016
Vitamin D and FBS	0.049	0.834
Vitamin D and PP	-0.665	0.018
Vitamin D and GPx	0.342	0.452
Vitamin D and SOD	0.205	0.697
GPx and HbA1c	-0.465	0.429
SOD and HbA1c	-0.138	0.825

When  $P < 0.05$ , it is statistically significant. HbA1c = Glycated hemoglobin; FBS = Fasting blood sugar; PP = Postprandial blood sugar; GPx = Glutathione peroxidase; SOD = Superoxide dismutase

parameters in patients with T2DM. There was a significant negative correlation between serum Vitamin D levels and HbA1c ( $P = 0.016$ ), and also there was a negative correlation between serum Vitamin D levels and PP ( $P = 0.018$ ), but no statistical correlation was shown between serum Vitamin D levels and FBS, GPx, and SOD. In addition, GPx and SOD had no statistical correlation with HbA1c.

## DISCUSSION

T2DM is a progressive disease characterized by insulin resistance and  $\beta$ -cell dysfunction that ultimately leads to altered insulin secretion.<sup>[9]</sup> The pathogenesis of T2DM is multifactorial. Environmental factors play an important role either as triggers or even have protective role.<sup>[9,20]</sup> One among the environmental factors which may play a role in T2DM pathogenesis is Vitamin D deficiency.<sup>[21]</sup> Vitamin D plays a wide range of functions in our body such as regulation of mineral homeostasis, bone remodeling, and also plays a role in immune system.<sup>[22]</sup> Apart from these well-known functions, many studies have shown that Vitamin D also plays an important role in  $\beta$ -cell function, insulin sensitivity, and secretion by both direct and indirect actions.<sup>[22]</sup>

In our study, we found that serum 25(OH)D levels were significantly lower in the group of T2DM patients compared to control group. Similar results are reported in previous studies.<sup>[23-25]</sup> Need *et al.*<sup>[26]</sup> showed that the patients who had higher levels of Vitamin D concentration had lower FBS in comparison with the other groups. In contrast, other studies, have not shown any difference in 25(OH)D between patients with diabetes compared to normal population.<sup>[27,28]</sup>

In T2DM, the role of Vitamin D was suggested from the presence of Vitamin D receptors (VDR) on the pancreatic  $\beta$ -islet cells. In these cells, the biologically active metabolite of Vitamin D (i.e., 1,25-dihydroxy Vitamin D<sub>1,25(OH)<sub>2</sub>D</sub>) enhances insulin production and secretion via its action on the VDR.<sup>[29]</sup> Several studies demonstrated a relationship between single-nucleotide polymorphisms in the genes regulating VDR and Vitamin D binding protein and glucose intolerance and insulin secretion.<sup>[30-32]</sup> This further supports a role for Vitamin D in T2DM and may explain the reduced overall risk of the disease in subjects who ingest >800 IU/day of Vitamin D.<sup>[33]</sup> However, an alternative, perhaps related, explanation was proposed for the role of Vitamin D in the prevention of T2DM based on its potent immunomodulatory functions.<sup>[34]</sup> 1,25(OH)<sub>2</sub>D modulates the production of the immunostimulatory interleukin (IL)-12 and the immunosuppressive IL-10,<sup>[35]</sup> and VDRs are present in most types of immune cells.<sup>[36]</sup> Vitamin D protect  $\beta$ -cells against cytokine-induced apoptosis.<sup>[37]</sup>

In our study, Vitamin D levels were found to be negatively correlated with HbA1c levels. This was in agreement with

other studies.<sup>[38,39]</sup> HbA1c is considered an indicator of average blood glucose concentrations during the preceding 2–3 months and thus a long-term marker of glucose homeostasis.<sup>[40]</sup> There was a negative correlation between Vitamin D levels and PP, but no correlation between fasting glycemia and 25(OH)D was found, although that, Vitamin D levels being related to glycemic control where HbA1c reflects glucose control over time and it is more accurate than FBS and PP.

We found a nonsignificant difference in SOD activity in patients with T2DM when compared to controls. SOD is considered to be the first line of defense against oxidation stress; it protects the body against active oxygen-free radicals by scavenging excess superoxide to form hydrogen peroxide which is then converted to water by GPx enzyme.<sup>[41]</sup> Our results revealed that GPx activity was significantly low in patients with T2DM, indicating decreased scavenging capacity of glutathione-dependent antioxidant defense system against elevated lipid peroxidation processes in these patients. There was no significant correlation between serum levels of 25(OH)D and activities of GPx and SOD enzymes in patients with T2DM in our study.

There is contradiction about the activity of antioxidant enzymes in diabetes mellitus. Both increased and decreased activities of these enzymes were reported in experimental and trial studies.<sup>[42]</sup> Saedisomeolia *et al.*<sup>[43]</sup> showed lower activity of SOD and higher activities of GPx and glutathione reductase (GR) in patients with T2DM compared to controls. The main new finding of their study was determining the association between serum levels of 25(OH)D and activity of antioxidant enzymes in patients with T2DM and healthy controls. Results of their study indicated an inverse relationship between serum levels of 25(OH)D and activities of GPx and GR and a positive trend with SOD in patients with diabetes. Hisalkar *et al.*<sup>[44]</sup> revealed a significant fall in both SOD and GPx activities in patients with T2DM when compared to controls which was in agreement with our results regarding GPx activity. Similar findings were reported by various authors.<sup>[45,46]</sup>

It was suggested that in the early stage of T2DM, the antioxidant defense system counters the effects of increased free radicals, so it was supposed that the antioxidant enzymes activities increased as a compensatory response to oxidative stress, but by the advanced stage, the balance between generation of free radicals and antioxidant defense is impaired as a result of decreased antioxidant activities due to their possible depletion.<sup>[47]</sup> There is a considerable body of evidence indicating that hyperglycemia may interfere with natural defense of the antioxidant system, in addition to increasing the production of free radicals.<sup>[48]</sup> Since SOD enzyme is part of the first line of defense against free radicals, it is expected that the activity of this enzyme

may be affected by oxidative stress before the other antioxidant enzymes.<sup>[49]</sup> Taheri *et al.*<sup>[47]</sup> indicated that SOD activity was lower in patients with diabetes compared with healthy controls. There is evidence to show that hyperglycemia is accompanied by the loss of Cu<sup>2+</sup>, which is an essential cofactor in SOD activity, and SOD is inactivated by glycosylation in erythrocytes.<sup>[49]</sup>

As hyperglycemia, a hallmark of diabetic condition, depletes natural antioxidants and facilitates the production of reactive oxygen species (ROS) through glucose autoxidation and nonenzymatic glycation of proteins,<sup>[50]</sup> and as Vitamin D levels were related to glycemic control in patients with T2DM as indicated in our study, Vitamin D supplementation can improve oxidative stress in patients with diabetes by improving glucose control. Several studies on experimental models showed that Vitamin D has antioxidant properties.<sup>[16,17,49,51]</sup> Wiseman<sup>[52]</sup> reported that Vitamin D3 can inhibit lipid peroxidation induced by iron in brain liposome; therefore, Vitamin D could serve as cellular membrane antioxidant. Anticancer activity of Vitamin D is also attributable to its antioxidant property.<sup>[53]</sup> Mukhopadhyay *et al.*<sup>[17]</sup> also conducted a study in murine lymphoma and concluded that the anticancer effect of Vitamin D3 is mainly through its antioxidant potential. Vitamin D can be considered as a casual antioxidant which scavenges ROS in the first stage before activation of other stress-sensitive response pathways; on the other hand, Vitamin E or other antioxidants may be considered a more “symptomatic” rather than a causal treatment for oxidative stress because these antioxidants scavenge the already formed oxidants.<sup>[54]</sup>

This study showed that Vitamin D levels appear to be lower in patients with T2DM than in the control group and Vitamin D levels were related to glycemic control in T2DM. The study had some limitations; the sample size was small and the sunlight exposure of each individual varies on a daily basis.

## CONCLUSION

Low level of Vitamin D might play a significant role in T2DM pathogenesis and this finding may have therapeutic implications as cautious Vitamin D supplementation may improve glycemic control and oxidative stress in T2DM.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

## AUTHORS' CONTRIBUTIONS

MSE contributed in the conception and design of the work, coordinated and carried out all experiments, performed

statistical analysis, participated in manuscript preparation, revised the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. IMI contributed in the conception of the work, collected samples from patients, provided assistance for all experiments, revised the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. MMA contributed in the conception and design of the work, prepared the manuscript and revised the draft, approval of the final version of the manuscript, and agreed for all aspects of the work.

## REFERENCES

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047-53.
2. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: Systematic review and meta-analysis. *East Mediterr Health J* 2009;15:591-9.
3. Heaney RP. Functional indices of Vitamin D status and ramifications of Vitamin D deficiency. *Am J Clin Nutr* 2004;80 6 Suppl: 1706S-9S.
4. Holick MF. High prevalence of Vitamin D inadequacy and implications for health. *Mayo Clin Proc* 2006;81:353-73.
5. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006;84:18-28.
6. Jolfaie NR, Rouhani MH, Onvani S, Azadbakht L. The association between Vitamin D and health outcomes in women: A review on the related evidence. *J Res Med Sci* 2016;21:76.
7. Chagas CE, Borges MC, Martini LA, Rogero MM. Focus on Vitamin D, inflammation and type 2 diabetes. *Nutrients* 2012;4:52-67.
8. Lim S, Kim MJ, Choi SH, Shin CS, Park KS, Jang HC, *et al.* Association of Vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. *Am J Clin Nutr* 2013;97:524-30.
9. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of Vitamin D in the pathogenesis of type 2 diabetes mellitus. *Diabetes Obes Metab* 2008;10:185-97.
10. Lau SL, Gunton JE, Athayde NP, Byth K, Cheung NW. Serum 25-hydroxyvitamin D and glycated haemoglobin levels in women with gestational diabetes mellitus. *Med J Aust* 2011;194:334-7.
11. Ceriello A. Oxidative stress and glycemic regulation. *Metabolism* 2000;49 2 Suppl 1:27-9.
12. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. *Biomed Pharmacother* 2005;59:365-73.
13. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. *Endocr Rev* 2002;23:599-622.
14. Muth CM, Glenz Y, Klaus M, Radermacher P, Speit G, Leverage X. Influence of an orally effective SOD on hyperbaric oxygen-related cell damage. *Free Radic Res* 2004;38:927-32.
15. Bhabak KP, Mughesh G. Functional mimics of glutathione peroxidase: Bioinspired synthetic antioxidants. *Acc Chem Res* 2010;43:1408-19.
16. Karmakar R, Banik S, Chatterjee M. Inhibitory effect of Vitamin D3 on 3'-methyl-4-dimethyl-amino-azobenzene-induced rat hepatocarcinogenesis: A study on antioxidant defense enzymes. *J Exp Ther Oncol* 2002;2:193-9.

17. Mukhopadhyay S, Singh M, Chatterjee M. Vitamin D3 as a modulator of cellular antioxidant defence in murine lymphoma. *Nutr Res* 2000;20:91-102.
18. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. *Clin Chem* 1988;34:497-500.
19. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med* 1967;70:158-69.
20. Angermayr L, Melchart D, Linde K. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus – A systematic review of randomized controlled trials. *Ann Behav Med* 2010;40:49-64.
21. Taylor AV, Wise PH. Vitamin D replacement in Asians with diabetes may increase insulin resistance. *Postgrad Med J* 1998;74:365-6.
22. Harinarayan CV. Vitamin D and diabetes mellitus. *Hormones (Athens)* 2014;13:163-81.
23. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, *et al.* Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: Results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). *Diabetes Care* 2011;34:1133-8.
24. Taheri E, Saedisomeolia A, Djalali M, Qorbani M, Madani Civi M. The relationship between serum 25-hydroxy Vitamin D concentration and obesity in type 2 diabetic patients and healthy subjects. *J Diabetes Metab Disord* 2012;11:16.
25. Bayani MA, Akbari R, Banasaz B, Saeedi F. Status of Vitamin-D in diabetic patients. *Caspian J Intern Med* 2014;5:40-2.
26. Need AG, O'Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. *Clin Endocrinol (Oxf)* 2005;62:738-41.
27. Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on Vitamin D and Vitamin B12 levels in patients with type 2 diabetes mellitus. *Endocr Pract* 2012;18:179-84.
28. Payne JF, Ray R, Watson DG, Delille C, Rimler E, Cleveland J, *et al.* Vitamin D insufficiency in diabetic retinopathy. *Endocr Pract* 2012;18:185-93.
29. Holick MF. Diabetes and the Vitamin D connection. *Curr Diab Rep* 2008;8:393-8.
30. Szathmary EJ. The effect of Gc genotype on fasting insulin level in Dogrib Indians. *Hum Genet* 1987;75:368-72.
31. Hirai M, Suzuki S, Hinokio Y, Hirai A, Chiba M, Akai H, *et al.* Variations in Vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. *J Clin Endocrinol Metab* 2000;85:1951-3.
32. Baier LJ, Dobberfuhr AM, Pratley RE, Hanson RL, Bogardus C. Variations in the Vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. *J Clin Endocrinol Metab* 1998;83:2993-6.
33. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, *et al.* Vitamin D and calcium intake in relation to type 2 diabetes in women. *Diabetes Care* 2006;29:650-6.
34. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. *Am J Clin Nutr* 2004;80 6 Suppl: 1717S-20S.
35. DeLuca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. *FASEB J* 2001;15:2579-85.
36. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. *Arch Biochem Biophys* 2000;374:334-8.
37. Riachy R, Vandewalle B, Kerr Conte J, Moerman E, Sacchetti P, Lukowiak B, *et al.* 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: Implication of the antiapoptotic protein A20. *Endocrinology* 2002;143:4809-19.
38. Cimbek A, Gürsoy G, Kılıç Z, Acar Y, Demirbaş B, Bayram M, *et al.* Serum 25 hydroxy Vitamin D3 levels in type 2 diabetic patients. *Med Bull Haseki* 2013;51:89-94.
39. Kostoglou-Athanassiou I, Athanassiou P, Gkountouvas A, Kaldrymides P. Vitamin D and glycemic control in diabetes mellitus type 2. *Ther Adv Endocrinol Metab* 2013;4:122-8.
40. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, *et al.* Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. *Arch Intern Med* 2004;164:1627-32.
41. Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. *Clin Biochem* 1999;32:595-603.
42. Maritim AC, Sanders RA, Watkins JB 3<sup>rd</sup>. Diabetes, oxidative stress, and antioxidants: A review. *J Biochem Mol Toxicol* 2003;17:24-38.
43. Saedisomeolia A, Taheri E, Djalali M, Djazayeri A, Qorbani M, Rajab A, *et al.* Vitamin D status and its association with antioxidant profiles in diabetic patients: A cross-sectional study in Iran. *Indian J Med Sci* 2013;67:29-37.
44. Hisalkar PJ, Patne AB, Fawade MM, Karnik AC. Evaluation of plasma superoxide dismutase and glutathione peroxidase in type 2 diabetic patients. *Biol Med* 2012;4:65-72.
45. Singhania N, Puri D, Madhu SV, Sharma SB. Assessment of oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy. *QJM* 2008;101:449-55.
46. Sailaja YR, Baskar R, Saralakumari D. The antioxidant status during maturation of reticulocytes to erythrocytes in type 2 diabetics. *Free Radic Biol Med* 2003;35:133-9.
47. Taheri E, Djalali M, Saedisomeolia A, Moghadam AM, Djazayeri A, Qorbani M. The relationship between the activities of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. *J Diabetes Metab Disord* 2012;11:3.
48. Karasu C. Glycooxidative stress and cardiovascular complications in experimentally-induced diabetes: Effects of antioxidant treatment. *Open Cardiovasc Med J* 2010;4:240-56.
49. Hamden K, Carreau S, Jamoussi K, Miladi S, Lajmi S, Aloulou D, *et al.* 1Alpha, 25 dihydroxyvitamin D3: Therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. *J Nutr Sci Vitaminol (Tokyo)* 2009;55:215-22.
50. Baynes JW. Role of oxidative stress in development of complications in diabetes. *Diabetes* 1991;40:405-12.
51. Cetinkalp S, Delen Y, Karadeniz M, Yüce G, Yılmaz C. The effect of 1alpha, 25(OH)2D3 vitamin over oxidative stress and biochemical parameters in rats where type 1 diabetes is formed by streptozotocin. *J Diabetes Complications* 2009;23:401-8.
52. Wiseman H. Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. *FEBS Lett* 1993;326:285-8.
53. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. *Nat Rev Cancer* 2007;7:684-700.
54. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. *Diabetes Care* 2003;26:1589-96.